Stockscreener 앱 받기
90.31
5.18%
4.45
시간 외 거래:
95.06
4.75
+5.26%
전일 마감가:
$85.86
열려 있는:
$84.71
하루 거래량:
993.81K
Relative Volume:
1.30
시가총액:
$6.17B
수익:
$189.76M
순이익/손실:
$-196.54M
주가수익비율:
-29.05
EPS:
-3.1087
순현금흐름:
$-156.63M
1주 성능:
-0.92%
1개월 성능:
-12.46%
6개월 성능:
-5.99%
1년 성능:
+63.58%
1일 변동 폭
$84.00
$90.53
1주일 범위
$82.00
$91.28
52주 변동 폭
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
90.31 | 5.86B | 189.76M | -196.54M | -156.63M | -3.1087 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | RBC Capital Mkts | Outperform |
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Awaits FDA Decision On Expanded Use Of Imcivree In Hypothalamic Obesity - RTTNews
HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target - MSN
Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism - Insider Monkey
H.C. Wainwright cuts Rhythm Pharmaceuticals stock price target on trial miss - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) expected to beat earnings estimates: Should you buy? - MSN
HC Wainwright Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals: EMANATE Setback but Validated MC4R Mechanism and Pipeline Optionality Support Lowered $100 Buy Rating - TipRanks
HC Wainwright & Co. Lowers Price Target for Rhythm Pharmaceutica - GuruFocus
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Stryker (SYK) and Esperion (ESPR) - The Globe and Mail
Focus Shifts To Rhythm’s Imcivree Hypothalamic Obesity Opportunity After Phase III Miss - Citeline News & Insights
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Weakness And Strong Long Term Returns - Yahoo Finance
Is It Too Late To Consider Rhythm Pharmaceuticals (RYTM) After Its 4x Three Year Surge? - simplywall.st
Wall Street Recap: Can Rhythm Pharmaceuticals Inc ride the EV waveSwing Trade & Daily Profit Maximizing Tips - baoquankhu1.vn
Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Quote, News & History - Benzinga
RYTM: Morgan Stanley Lowers Price Target to $136 While Maintaini - GuruFocus
Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat - Investor's Business Daily
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $131.00 at Citigroup - MarketBeat
Post-Emanate, Rhythm’s next Imcivree news aHO lot better? - BioWorld MedTech
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $130.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Rhythm Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Citizens Lowers Price Target for Rhythm Pharmaceuticals (RYTM) W - GuruFocus
Citizens Jmp Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $152.00 - MarketBeat
Needham cuts Rhythm Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Analyst Rating Update: Price Targe - GuruFocus
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - MSN
RYTM: Morgan Stanley Lowers Price Target to $136 While Maintaining Overweight Rating | RYTM Stock News - GuruFocus
Needham & Company LLC Lowers Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $130.00 - MarketBeat
Morgan Stanley Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $139.00 Price Target at Bank of America - MarketBeat
Stock Market Today: Dow, S&P 500 Futures Tick Up As Oil Prices Rise, US Allies Reject Trump's Hormuz Call— Uber, Lululemon, Cisco In Focus (UPDATED) - Benzinga
RYTM: Needham Maintains Buy Rating While Lowering Price Target | - GuruFocus
Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints - Benzinga
RBC Lowers Price Target on Rhythm Pharmaceuticals to $130 From $140, Keeps Outperform, Speculative Risk - marketscreener.com
Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Aquatic Capital Management LLC - MarketBeat
Stocks Showing Improving Market Leadership: Rhythm Pharmaceuticals Earns 81 RS Rating - Investor's Business Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE TrialSlideshow (NASDAQ:RYTM) 2026-03-17 - Seeking Alpha
Rhythm Pharma shares fall as obesity drug trial fails to meet main goal - Investing.com South Africa
Stifel reiterates Rhythm Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial - Bitget
Rhythm Pharmaceuticals Reports Mixed Phase 3 EMANATE Results - TipRanks
Rhythm Pharmaceuticals (RYTM) Shares Results from EMANATE Trial - GuruFocus
Phase 3 EMANATE trial miss at Rhythm Pharmaceuticals (Nasdaq: RYTM) - Stock Titan
Trust for Rhythm Pharmaceuticals (RYTM) director receives 4,199 shares - Stock Titan
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial - marketscreener.com
Obesity drug trial misses goal, yet some patients cut BMI by 9.7% - Stock Titan
Rhythm Pharmaceuticals: Rare Genetic Obesity Player With Upcoming PDUFA (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision (NASDAQ:RYTM) - Seeking Alpha
First Light Asset Management LLC Takes $18.23 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Cinctive Capital Management LP Sells 35,781 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):